[Ip-health] [HEALTHGAP] The Medicines Patent Pool's Licenses with Gilead Jeopardize Access to Treatment

Jamie Love james.love at keionline.org
Mon Jul 25 08:23:15 PDT 2011

Before addressing the details of the ITPC/I-Mak analysis, I would like to
address the issue of the 5 percent of the royalty fee to the patent pool.
 Clearly this gives the patent pool, which is an NGO, a certain degree of
independence from any particular donor, which has positives and negatives.
 In terms of sustainability of the pool, assuming anyone wants a pool to
exist at all, how do you think its operating costs should be financed?


On Mon, Jul 25, 2011 at 9:44 AM, Gregg Gonsalves
<gregg.gonsalves at gmail.com>wrote:

> Dear colleagues,
> I urge you to read this paper in full.  It is an ITPC/I-MAK analysis
> of the Medicines Patent Pool and its recent licenses negotiated with
> Gilead Sciences Inc.
> While many have praised the licenses, others have criticized them on
> narrow grounds, primarily on the exclusion of middle income countries.
> The analysis here shows that the problems with these licenses and with
> the Medicines Patent Pool are far broader and more dangerous.
> These agreements strengthen patent protections on drugs and their
> chemical precursors, weakening the ability of countries to provide
> vital medicines to their own people and to other countries with
> tremendous need for these drugs.
> Furthermore, the Medicines Patent Pool has instituted a 5% fee to be
> paid to it by Gilead for the identification and administration of
> these licenses, which we believe is an egregious conflict of interest.
> We are calling on the Patent Pool Governance Board to censure these
> licenses. We also demanding a moratorium on current negotiations with
> Bristol Myers Squibb and Boehringer-Ingelheim until a broad technical
> consultation with representatives from affected communities can be
> held to discuss the future and reform of the Medicines Patent Pool's
> mandate.
> Gregg
> http://www.i-mak.org/storage/ITPC%20I-MAK%20-%20The%20Broader%20Implications%20of%20the%20MPP%20and%20Gilead%20Licenses%20on%20Access%20-%20FINAL%2025-7-2011.pdf
> --
> Gregg Gonsalves
> 100 York Street
> University Towers, 10-D
> New Haven, CT 06511
> Email: gregg.gonsalves at gmail.com or gregg.gonsalves at yale.edu
> Mobile: +1-203-606-9149
> _______________________________________
> https://lists.critpath.org/mailman/listinfo/healthgap
> HealthGAP is a public list. To post, send to healthgap at critpath.org. To
> subscribe, unsubscribe, or for help with your account, send an email to
> info at healthgap.org
> www.healthgap.org

James Love.  Knowledge Ecology International
http://www.keionline.org, +1.202.332.2670, US Mobile: +1.202.361.3040,
Geneva Mobile: +41.76.413.6584, efax: +1.888.245.3140.

More information about the Ip-health mailing list